title: Effects of bezafibrate on HDL2/HDL3 ratio in postmenopausal hypertriglyceridemic women.
abstract: The short-term effects of bezafibrate on high-density lipoprotein cholesterol quality and triglyceride-rich lipoprotein metabolism in 186 postmenopausal hypertriglyceridemic women were investigated. Patients were randomized to an untreated group and to bezafibrate (400 mg/d) for 6 months. Fasting lipid concentrations, high-density lipoprotein 2, and high-density lipoprotein 3 levels were measured at baseline and after 3 and 6 months. At 3 months, bezafibrate had significantly decreased mean serum triglycerides and remnant-like particle cholesterol levels (105.7 +/- 43.4 mg/dL and 5.33 +/- 2.1 mg/dL, P < .001, respectively) from baseline values (232.5 +/- 63.9 mg/dL and 9.69 +/- 3.8 mg/dL, respectively). It also maintained lower total cholesterol, low-density lipoprotein cholesterol, triglycerides, and remnant-like particle cholesterol concentrations to 6 months. After 3 months, it significantly increased mean serum high-density lipoprotein cholesterol (55.1 +/- 14.7 vs 64.8 +/- 12.1 mg/dL; P < .0001) and maintained higher high-density lipoprotein cholesterol at 6 months. The high-density lipoprotein 2-high-density lipoprotein 3 ratio was decreased after 3 months of therapy with bezafibrate (2.13 +/- 0.68) from the baseline (2.42 +/- 0.71) (P < .01).
authors.affiliation: Department of Obstetrics and Gynecology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan. gyn003@poh.osaka-med.ac.jp
authors.forename: Takahisa
authors.initials: T
authors.lastname: Ushiroyama
authors.forename: Kou
authors.initials: K
authors.lastname: Sakuma
authors.forename: Sakura
authors.initials: S
authors.lastname: Nosaka
mesh_terms: D001629:Bezafibrate / Q000009:adverse effects / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy*; D015228:Hypertriglyceridemia / Q000097:blood*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008075:Lipoproteins, HDL / Q000097:blood*; D008875:Middle Aged; D017698:Postmenopause / Q000097:blood*
chemical_list: D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D002784:Cholesterol; D001629:Bezafibrate